JNJ ▲ +0.1% - Johnson & Johnson $JNJ - Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study 25-SEP-2026 07:30 AM ET